Leucocyte-platelet haemocomponents for topical use: regenerative potentiality.

Wider and wider is the interest in different clinical ambits in the application of haemocomponents produced from peripheral blood for regenerative purposes. These are mainly made up of concentrated platelets capable of releasing locally growth factor (GF) that stimulates tissue regeneration. Our group has devised a method to produce a new leucocyte-platelet haemocomponent enriched in fibrinogen that integrates the GF stimulus with the presence of cells involved in the regenerative processes: monocytes and stem cells. The use of the cell separator to collect these haemocomponents from peripheral blood has allowed us to realize a safe standardized product, with good regenerative potentiality and reasonable costs. This is obtained by modifying some parameters of separation, and without cell manipulation.

New method to produce hemocomponents for regenerative use from peripheral blood: integration among platelet growth factors monocytes and stem cells.

Recent studies have shown the importance of monocytes/macrophageses and of CD34+ progenitors in tissue regeneration processes. These cells, obtained generally from bone marrow, are seen in damaged tissue. We have studied a method to collect from the peripheral blood, using a cell separator and without stimulation of the patient/donor, a leukocyte platelet concentrated hemocomponent (CLP) for regenerative use which contains platelets, monocytes/macrophages, fibrinogen and CD34+ cells. We appraised the composition and cell functionality of the final hemocomponent during production and cryoconservation. The results show a positive increase in concentration values, in comparison with the pre-collection, of the cells that were involved in regeneration; i.e. the platelets, monocytes and CD34+ cells. These concentrations were also maintained at an effective level during cryoconservation of the hemocomponent. The CLP also demonstrated positive clonogenic potential in culture, showing that the CD34+ progenitors involved in CFU formation are functional in the fresh and thawed product. In brief we have shown that it is possible to produce, in a simple way, a hemocomponent for regenerative use that is standardized, reliable, and is economically feasible.